Allogene tx

US Private Finance Raise of the year

The Award

This award recognises a company that has successfully completed a significant, impactful or transformational private fundraise between 1 September 2017 and 1 September 2018.

Judges paid particular attention to:

  • Amount and series/type of funds raised.
  • Process/speed/allocation fulfilment of securing significant new funds.
  • Level/reputation of new investor(s) attracted.
  • Post-finance allocation/use of proceeds.
  • Level of value creation/value realisation from raise. 

Company Description  

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.